Clinical-Stage Products Focused on Novel Targets
Oncternal Therapeutics is a clinical-stage oncology company developing potentially first-in-class, novel therapies that target a broad spectrum of cancers with large unmet medical need. By leveraging pathways absent or minimally expressed in normal cells or tissue, we aim to impact cancer cell growth while reducing potential harm to healthy cells. We continue to investigate the potential to treat additional malignancies with our product candidates and intend to broaden the indications we are studying.
On September 12, 2024, Oncternal announced it was discontinuing its clinical trials and exploring strategic alternatives.